Blood CancerArchives
Daratumumab/Bortezomib/Thalidomide/Dexamethasone in Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Blood Cancer 1 min.
Previous results from CASSIOPEIA (NCT02541383) demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance versus observation...
Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification models
Blood Cancer 6 min.
The term “big data” has become a buzzword in medical literature, yet its interpretation varies significantly between medical professionals and data scientists. For instance, ImageNet1 (https://www.image-net.org/)—an object-based image database frequently used for training and validation...
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management
Blood Cancer 3 min.
The small molecule selective inhibitor of B-cell lymphoma-2 (BCL-2), venetoclax [1], was approved in Japan in 2021 with azacitidine (VEN/AZA) or low-dose cytarabine (VEN/LDAC) for acute myeloid leukemia (AML) [2]. Despite significantly improving AML outcomes versus a hypomethylating agent (HMA) or low-dose...
An 8-year-old girl with secondary histiocytic sarcoma with BRAFV600 mutation following T-cell acute lymphoblastic leukemia demonstrating stable disease for 3 years on dabrafenib and trametinib – a case report and literature review
Blood Cancer 3 min.
Histiocytic sarcoma (HS) developing as a secondary neoplasm is extraordinarily rare [1] in childhood and presents a diagnostic challenge. Dismal prognosis is expected due to rapid progression and poor response to therapy [2]. No optimal treatment has been defined and standardized [3]. Among the reported...
Proceedings of the 4th European Congress controversies in Leukemias, held in Brussels, Belgium, 20-21 November, 2023.
Blood Cancer 1 min.
AML Classifications: WHO vs ICC 2022 Update The following is a summary of the article “Definitions of Acute Myeloid Leukaemia and their clinical significance according to the WHO 2022 and ICC classification” by Donata Backhaus et al (University of Leipzig Medical Center, Germany), which...
